Clinical Study

Clinicopathological and Immunohistochemical Characterisation of Gastric Schwannomas in 29 Cases

Table 1

Clinicopathologic features of 29 cases of gastric schwannomas.

CaseAge (y)/sexClinical presentationSiteSize (cm)Mitoses/50 HPFsOutcomeFollow-up time (mo)

154/FIncidentalGastric antrum3.50ANED157
278/MGI bleedingGastric fundus6.52DUC132
381/FEpigastric pain and mass palpated on a doctor’s visit for another diseaseGastric body (lesser curvature)7.01DUC108
443/FGastric painGastric antrum4.06ANED72
554/FIncidentalGastric fundus5.34ANED47
667/FIncidentalGastric antrum3.21ANED23
778/MPoor appetiteGastric antrum2.60DUC37
873/FGastric distressGastric body (greater curvature)4.40ANED11
954/FIncidentalGastric antrum2.92DUC25
1046/FGastric painGastric body (greater curvature)5.26ANED24
1176/FWeight lossGastric antrum2.11ANED21
1264/MIncidental on CT for lung cancer followupGastric fundus7.59ANED14
1357/MDetected during abdominal sonography for cholecystolithiasis Gastric fundus4.32ANED14
1445/MIncidentalGastric body (lesser curvature)5.51ANED10
1566/FGI bleedingGastric body (lesser curvature)4.00LTF0
1679/MIntermittent gastric discomfortGastric antrum3.00ANED6
1752/MDetected during abdominal sonography for cholecystolithiasisGastric antrum6.55ANED132
1867/MGastric painGastric body (greater curvature)6.715DUC80
1973/FHematemesis, melenaGastric antrum5.220DMR15
2061/MGastric painGastric antrum5.716ANED28
2155/FNausea and gastric discomfortGastric body (lesser curvature)3.81ANED93
2267/FNausea and occult blood in stoolGastric fundus7.93DUC81
2360/MIncidentalGastric fundus5.72ANED49
2466/FFullness of stomachGastric body (greater curvature)6.95ANED60
2565/FDetected during CT for unknown symptomsGastric body (greater curvature)6.219DMR58
2643/FEpigastric discomfortcardia3.83ANED99
2778/FFullness of stomachGastric body (greater curvature)4.21ANED68
2869/MAbdominal painGastric body (greater curvature)6.00DUC55
2970/FGastric painGastric body (lesser curvature)7.21ANED79

DUC: died of unrelated causes; ANED: alive with no evidence of disease; LF: lost to followup; DMR: died of metastasis or recurrent of the primary disease.